COMMUNIQUÉ DE PRESSE
News
-
-
COMMUNIQUÉ DE PRESSE
Mainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket Approval
Mainz Biomed provides Q1 2025 corporate update on FDA premarket approval path, including study enrollment, partnership with Liquid Biosciences and labor team w ag, and product launches. CEO Guido Baechler comments on progress -
-
-
COMMUNIQUÉ DE PRESSE
Tharimmune Advances TH104 for Prophylaxis Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback
Tharimmune, Inc. receives positive FDA feedback on TH104, a buccal film formulation of nalmefene for prophylaxis of opioid exposure in military personnel & first responders -
-
-
-
-
COMMUNIQUÉ DE PRESSE
Pinetree Capital Ltd Announces Unaudited Financial Results for the Period Ended March 31, 2025 and Leave of Absence of Chief Investment Officer
Pinetree Capital Ltd. announces unaudited financial results for the quarter ended March 31, 2025. BVPS increased to $9.41. Equity investments at fair value totaled $84,687. Chief Investment Officer on leave
